Comparative Pharmacology
Head-to-head clinical analysis: REGROTON versus SERPASIL ESIDRIX 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REGROTON versus SERPASIL ESIDRIX 2.
REGROTON vs SERPASIL-ESIDRIX #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
None Documented
None Documented
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination